FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | DC | 20549 |
|---------------|------|-------|
| wasiiiiqtoii, | D.C. | 20049 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | |
| hours per response. | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Groen Eric | | | 2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI] | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director | | | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------|----|----|--|
| (Last) 2051 RIN |) (First) (Middle) | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/21/2024 | | | | |) | X Officer (give title Other (specification) General Counsel | | | | | | |
| (Street) SAN JOS | SE C. | A | 95131 | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | Line | ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | |
| (City) | (S | tate) | (Zip) | | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | o satisfy | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | 2A. Deemed Execution Date if any (Month/Day/Yea | | e, Transaction Disposed Of (D) Code (Instr. | | | es Acquired (A) or Of (D) (Instr. 3, 4 and 5 | | 5. Amount of Securities Beneficially Owned Following Reported | | : Direct I Indirect E str. 4) | 7. Nature of ndirect Beneficial Ownership Instr. 4) | | | |
| | | | | | Code | ٧ | Amount | (A) o (D) | r Price | Transacti (Instr. 3 a | tion(s) | | | | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | erivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any | | Co | ransaction Derivative Securities | | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4) | | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | | | | Cod | de V | (A) | (D) | Date Exercisable | | xpiration ate | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | 5) | |
| Stock Option (Right to Buy) | \$3.6 | 03/21/2024 | | A | | 323,500 | | (1) | 03 | 3/20/2034 | Class A Common Stock | 323,500 | \$0 | 323,50 | 00 | D | |

Explanation of Responses:

1. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024.

Eric Groen

03/22/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).